Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis

This study aims to compare the clinical efficacy and safety of BD111 injection in combination with standard therapy vs. standard therapy in herpes simplex virus type I stromal keratitis (HSK), providing preliminary confirmation of the clinical effectiveness of BD111 in combination with standard therapy.

Participants needed: 40
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Shanghai BDgene Co., Ltd.Updated: May 18, 2025Locations: 1
Eligibility criteria

Aged 18 to 70 years old; [+11]

Active ocular infection caused by other pathogens in the target eye or the fello... [+21]

Read more
Status: Recruiting

A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major

This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector encoding the human βA-T87Q-globin gene in patients with transfusion-dependent (TDT) β-thalassemia.

Participants needed: 9
Trial details
Phase: Phase 1Age: 3-35Biological sex: AllType: InterventionalSponsor: Shanghai BDgene Co., Ltd.Updated: Jun 24, 2024Locations: 3
Eligibility criteria

Participants aged 3 years (inclusive) to 18 years (exclusive), with no gender re... [+8]

Has a fully HLA-matched hematopoietic stem cell donor and is willing to receive... [+25]

Read more
Status: Recruiting

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia

This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector encoding the human βA-T87Q-globin gene in patients with transfusion-dependent (TDT) β-thalassemia.

Participants needed: 10
Trial details
Age: 6-35Biological sex: AllType: InterventionalSponsor: Shanghai BDgene Co., Ltd.Updated: Jun 14, 2024Locations: 1
Eligibility criteria

The tumor genes chip detection results about acute leukemia and myeloid tumor ge... [+5]

Availability of voluntary, fully HLA-matched hematopoietic cell donors, unless r... [+17]

Read more
Status: Recruiting

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia

This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector encoding the human βA-T87Q-globin gene in patients with transfusion-dependent (TDT) β-thalassemia.

Participants needed: 10
Trial details
Age: 3-18Biological sex: AllType: InterventionalSponsor: Shanghai BDgene Co., Ltd.Updated: Jun 14, 2024Locations: 1
Eligibility criteria

No eligiblity for allogeneic hematopoietic stem cell transplantation. [+4]

Availability of voluntary, fully HLA-matched hematopoietic cell donors, unless r... [+19]

Read more